Tech Company Financing Transactions
Nuclidium Funding Round
Nuclidium, based in Basel, received $98 million from Angelini Ventures, Kurma Partners and Neva SGR.
Transaction Overview
Company Name
Announced On
7/10/2025
Transaction Type
Venture Equity
Amount
$98,000,000
Round
Series B
Investors
Angelini Ventures (Lead Investor)
Kurma Partners (Lead Investor)
Neva SGR (Lead Investor)
Wellington Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the clinical development of its Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications, and expand its production and manufacturing capabilities through a global production network.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Im Erasmushaus, Bäumleingasse 18
Basel, 4051
Switzerland
Basel, 4051
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
NUCLIDIUM's vision is to address the unmet need in cancer medicine by providing personalised treatment options for cancer patients at every stage of their disease to improve long-term survival. Our therapeutic approach combines accurate diagnosis and staging of cancers at an early stage with a highly personalized treatment dose enabling less aggressive treatment and a significantly better quality of life for the patient.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Leila Jaafar-Thiel
Browse more venture capital transactions:
Prev: 7/10/2025: AirMDR venture capital transaction
Next: 7/10/2025: iCapital venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs